Successful prolonged use of recombinant human insulin-like growth factor-1 in a child with cystic fibrosis

Pediatr Pulmonol. 2011 Nov;46(11):1137-41. doi: 10.1002/ppul.21478. Epub 2011 May 26.

Abstract

Growth failure is a common and complicated process in children with cystic fibrosis (CF). Growth hormone, which is becoming a more commonly used agent in such patients, has demonstrated beneficial effects aside from increased growth velocity. Recently, insulin-like growth factor-1 has gained significant attention in the understanding of growth failure in children with CF. We report the successful prolonged use of recombinant human insulin-like growth factor-1 in an adolescent boy with CF, who demonstrated significant clinical benefits from the therapy.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / therapeutic use
  • Body Height / drug effects
  • Body Weight / drug effects
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / drug therapy*
  • Failure to Thrive / complications
  • Failure to Thrive / drug therapy*
  • Gene Deletion
  • Glycated Hemoglobin A / analysis
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Insulin-Like Growth Factor I / administration & dosage*
  • Liver Transplantation
  • Lung / drug effects
  • Lung / physiopathology
  • Male
  • Recombinant Proteins / administration & dosage*

Substances

  • Anti-Bacterial Agents
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Recombinant Proteins
  • hemoglobin A1c protein, human
  • Insulin-Like Growth Factor I